The abundance of clinical trials evaluating survival and treatment outcomes in women with breast cancer has resulted in a paradigm shift to more refined surgical treatment parameters and decreased the number of additional surgeries, according to researchers with Memorial Sloan-Kettering Cancer Center in New York, NY, but the ability of surgery to cure breast cancer remains unchanged. The researchers presented the results of their analyses on Wednesday, December 7, during the San Antonio Breast Cancer Symposium.

Women treated with accelerated partial breast irradiation (APBI) reported a significantly better quality of life (QOL) compared to women treated with whole breast irradiation (WBI), a group of Italian researchers has found. They presented their results on Wednesday, December 7, at the San Antonio Breast Cancer Symposium.

A group of British researchers has found that with only minimal changes in clinical parameters because of a lack of perfect correlation between pathologists’ results, there is a significant difference in the 10-year predicted mortality on Adjuvant! Online, a breast cancer risk assessment tool.

The original Tamoxifen Exemestane Adjuvant Multinational (TEAM) study found no significant differences for disease free survival (DFS) and overall survival (OS) at five years between exemestane monotherapy and sequential treatment (tamoxifen followed by exemestane), but there is still no universal agreement on optimal endocrine therapy.